Please use this identifier to cite or link to this item:
https://doi.org/10.18632/oncotarget.8223
Title: | ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction | Authors: | Shang, L Hao, J.-J Zhao, X.-K He, J.-Z Shi, Z.-Z Liu, H.-J Wu, L.-F Jiang, Y.-Y Shi, F Yang, H Zhang, Y Liu, Y.-Z Zhang, T.-T Xu, X Cai, Y Jia, X.-M Li, M Zhan, Q.-M Li, E.-M Wang, L.-D Wei, W.-Q Wang, M.-R |
Keywords: | anoctamin 1 membrane protein unclassified drug ANO1 protein, human anoctamin 1 tumor marker tumor protein adult Article cancer growth cancer prognosis cancer staging cancer survival cohort analysis controlled study esophagus biopsy esophagus cancer female human human tissue immunohistochemistry lymph node metastasis major clinical study male middle aged overall survival precancer predictive value protein analysis protein expression protein function survival prediction biosynthesis disease exacerbation esophagus esophagus tumor Kaplan Meier method metabolism pathology precancer prognosis squamous cell carcinoma Anoctamin-1 Biomarkers, Tumor Carcinoma, Squamous Cell Disease Progression Esophageal Neoplasms Esophagus Female Humans Immunohistochemistry Kaplan-Meier Estimate Male Middle Aged Neoplasm Proteins Precancerous Conditions Prognosis |
Issue Date: | 2016 | Citation: | Shang, L, Hao, J.-J, Zhao, X.-K, He, J.-Z, Shi, Z.-Z, Liu, H.-J, Wu, L.-F, Jiang, Y.-Y, Shi, F, Yang, H, Zhang, Y, Liu, Y.-Z, Zhang, T.-T, Xu, X, Cai, Y, Jia, X.-M, Li, M, Zhan, Q.-M, Li, E.-M, Wang, L.-D, Wei, W.-Q, Wang, M.-R (2016). ANO1 protein as a potential biomarker for esophageal cancer prognosis and precancerous lesion development prediction. Oncotarget 7 (17) : 24374-24382. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.8223 | Rights: | Attribution 4.0 International | Abstract: | Objectives: Anoctamin 1 (ANO1) has been found to be overexpressed in esophageal squamous cell carcinoma (ESCC) in our previous study. Herein we showed the clinical relevance of ANO1 alterations with ESCC and esophageal precancerous lesion progression. Results: ANO1 was detected in 38.1% (109/286) and 25.4% (77/303) of tumors in the two cohorts, but in none of morphologically normal operative margin tissues. ANO1 expression was significantly associated with a shorter overall survival (OS), especially in patients with moderately differentiated and stage IIA tumors. In 499 iodine-unstained biopsies from the endoscopic screening cohort in 2005-2007, all the 72 pathologically normal epithelial mucosa presented negative immunostaining, whereas ANO1 expression was observed in 3/11 tumors and 5/231 intraepithelial lesions. 7/8 ANO1-positive cases had developed unfavorable outcomes revealed by endoscopic follow-up in 2012. Analysis of another independent cohort of 148 intraepithelial lesions further confirmed the correlation between ANO1 expression and progression of precancerous lesions. 3/4 intraepithelial lesions with ANO1 expression had developed ESCC within 4-9 years after the initial endoscopic examination. Methods: Immunohistochemistry (IHC) was performed to examine ANO1 expression in surgical ESCC specimens and two independent cohorts of esophageal biopsies from endoscopic screening in high-incidence area of ESCC in northern China. Association between ANO1 expression, clinico-pathologic parameters, and the impact on overall survival was analyzed. Conclusions: Positive ANO1 is a promising biomarker to predict the unfavorable outcome for ESCC patients. More importantly, it can predict disease progression of precancerous lesions. | Source Title: | Oncotarget | URI: | https://scholarbank.nus.edu.sg/handle/10635/179931 | ISSN: | 19492553 | DOI: | 10.18632/oncotarget.8223 | Rights: | Attribution 4.0 International |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_18632_oncotarget_8223.pdf | 3.06 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License